GSK Marketing Planning | March 31 2013 | Calvin Cheung‚ Hussain Al Katib‚ Manpreet Budwal‚ Sandra Okechukwu | SOSTAC Review based on GlaxoSmithKline | Content Table of Contents 1.0 Introduction2 2.0 Situation Analysis3 2.1 PESTEL Analysis3 2.2 SWOT Analysis4 2.3 Boston Matrix5 2.4 Porter’s Five Forces Analysis6 3.0 Objectives8 4.0 Strategy9 4.1 Product9 4.2 Price9 4.3 Promotion9 4.4 Place10 4.5 Person10 4.6 Process10 4.7 Physical Evidence10 5.0 Tactics11 6.0 Action Plan12
Premium Marketing
advantage; Ansoff’s growth-vector matrix; portfolio analysis Introduction Based on a report conducted by a pharmaceutical magazine‚ Glaxosmithkline plc (Also known as GSK) is the fifth largest pharmaceutical company around the world (Contract Pharma‚ 2013). And it is also tided at No.112 on the 2013 ’s Global 2000 list‚ the list that manifests the 2000 most enormous companies in the world (Forbes‚ 2013). The researches above have indicated that GSK is one of the largest Transnational Corporation
Premium Strategic management Pharmaceutical industry
Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products‚ competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources Financial review 2009 Risk factors Governance and remuneration Our Board Our Corporate Executive Team Governance and policy Dialogue with shareholders
Premium Vaccine Rate of return Clinical trial
PROJECT REPORT ON WORKING CAPITAL MANAGEMENT WITH SPECIAL EMPHASIS ON VARIOUS TECHNIQUES OF INVENTORY CONTROL [pic] A training report submitted in partial fulfillment of the requirement for the degree Of MASTERS OF BUSINESS ADMINISTRATION (2010-2012) SUBMITTED TO: SUBMITTED BY:
Premium Inventory Financial ratio
Core issue: The case describes the events which lead to the merger of two large pharmaceutical giant Glaxo welcome and SmithKline beecham which lead to the formation of the entity GlaxoSmithKline. The core concern of the case is that although the newly merged company has invested heavily in R&D there is little evidence of success. Identification of supporting issues: These are some of the other issues that came up in the case which lead to the overall lack of success: * Significant
Premium
1) Product markets and geographic markets in which GSK is present GSK’s core mission is to “improve the quality of human life by enabling people to do more‚ feel better and live longer”. To achieve this mission‚ they operate in three main areas of businesses: the Pharmaceuticals (£18 Bn in 2012‚ or 68% of their revenues)‚ the Vaccines (£3.3 Bn‚ or 11% or their revenues) and the Consumer Healthcare (£5.1 Bn‚ or 19% of their revenues). In particular‚ the Pharmaceuticals cover medicines to treat a broad
Premium Medicine Pharmacology Food and Drug Administration
name] GSK – Successful Internal Innovation Question 1 Based on GSK’s past performance‚ what do you believe are the critical implementation issues for GSK with regards to internal innovation? Figure 4‚ 2‚ pg 132‚ The management of technology and innovation (White & Brighton) GSK key reason of success lies in its continuous radical change‚ by constantly inventing new drugs. Critical to the implementation issues of its internal innovation are raised below: Leadership GSK leadership
Premium Control system Control engineering Invention
Answer 2 …… Glaxosmithkline (GSK )‚ a research and development firm seeking to be excel in internal innovation through research on eight therapy areas- biopharmaceuticals‚ immune-inflammation‚ infectious diseases‚ metabolic pathways‚ neuroscience‚ oncology‚ ophthalmology and respiratory. To address these areas the firm in 2008 created 70 Discovery Performance Unit (DPUs) for future growth of the company. These 70 DPUs can affect the implementation effort in following ways to achieve success in
Premium Research Control theory Innovation
Executive Summary The purpose of this report was to review the codes of conduct of the Central Queensland University(CQU) and that of GlaxoSmithKline(GSK) in order to identify the different stakeholder affected‚ the ethical issues addressed by these documents‚ to explore the use of mandatory and voluntary practice in codes of conduct and finally to consider the application of corporate governance and transparency in these organizations. Stakeholders are the lifeblood of an organization. These
Premium Business ethics Ethics Corporate governance